Bone Biologics filed a patent application with the U.S. Patent and Trademark Office for its NELL-1 protein, according to a June 27 news release.
The patent applies to rhNELL-1 polypeptide and its use for treating bone conditions. The protein is used for spinal fusions.
If approved, the patent will support Bone Biologics’ intellectual property portfolio and plans to advance clinical development.
